BRPI0819902A2 - C2-c5-alquil-imidazol-bifosfonatos - Google Patents

C2-c5-alquil-imidazol-bifosfonatos

Info

Publication number
BRPI0819902A2
BRPI0819902A2 BRPI0819902-7A BRPI0819902A BRPI0819902A2 BR PI0819902 A2 BRPI0819902 A2 BR PI0819902A2 BR PI0819902 A BRPI0819902 A BR PI0819902A BR PI0819902 A2 BRPI0819902 A2 BR PI0819902A2
Authority
BR
Brazil
Prior art keywords
bisphosphonates
alkyl imidazole
imidazole
alkyl
imidazole bisphosphonates
Prior art date
Application number
BRPI0819902-7A
Other languages
English (en)
Inventor
Sven Weiler
Leo Widler
Jean-Michel Rondeau
Simona Cotesta
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819902(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0819902A2 publication Critical patent/BRPI0819902A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0819902-7A 2007-11-30 2008-11-26 C2-c5-alquil-imidazol-bifosfonatos BRPI0819902A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122016 2007-11-30
PCT/EP2008/066245 WO2009068567A1 (en) 2007-11-30 2008-11-26 C2-c5-alkyl-imidazole-bisphosphonates

Publications (1)

Publication Number Publication Date
BRPI0819902A2 true BRPI0819902A2 (pt) 2015-05-19

Family

ID=39154111

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819902-7A BRPI0819902A2 (pt) 2007-11-30 2008-11-26 C2-c5-alquil-imidazol-bifosfonatos

Country Status (24)

Country Link
US (2) US7977323B2 (pt)
EP (1) EP2225252B1 (pt)
JP (1) JP5244917B2 (pt)
KR (1) KR20100092035A (pt)
CN (1) CN101835787A (pt)
AR (1) AR069437A1 (pt)
AU (1) AU2008328797B2 (pt)
BR (1) BRPI0819902A2 (pt)
CA (1) CA2701516A1 (pt)
CL (1) CL2008003545A1 (pt)
CO (1) CO6280421A2 (pt)
CR (1) CR11362A (pt)
EA (1) EA201000860A1 (pt)
EC (1) ECSP10010321A (pt)
ES (1) ES2386851T3 (pt)
IL (1) IL204657A0 (pt)
MA (1) MA31895B1 (pt)
MX (1) MX2010005786A (pt)
NZ (1) NZ584219A (pt)
PE (1) PE20091038A1 (pt)
TN (1) TN2010000138A1 (pt)
TW (1) TW200932248A (pt)
WO (1) WO2009068567A1 (pt)
ZA (1) ZA201001992B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0910901A2 (pt) * 2008-04-04 2015-09-29 Novartis Ag composição farmacêutica com bisfosfonato
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
WO2011147038A1 (en) 2010-05-28 2011-12-01 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof
CN112980809B (zh) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2038692T4 (es) 1986-11-21 2012-02-10 Novartis Ag Procedimiento para la obtencion de acidos alcanodifosfonicos substituidos.
CZ282609B6 (cs) * 1991-02-26 1997-08-13 Norwich Eaton Pharmaceuticals, Inc. Směs v jednotné dávkovací formě pro léčení osteoporozy
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
AU2007304205A1 (en) 2006-10-05 2008-04-10 Novartis Ag Pharmaceutical compositions comprising bisphosphonates
JP2010522765A (ja) 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物

Also Published As

Publication number Publication date
AU2008328797B2 (en) 2011-11-03
ES2386851T3 (es) 2012-09-03
EP2225252B1 (en) 2012-06-27
US7977323B2 (en) 2011-07-12
PE20091038A1 (es) 2009-08-19
NZ584219A (en) 2012-03-30
CL2008003545A1 (es) 2009-06-05
EA201000860A1 (ru) 2010-12-30
WO2009068567A1 (en) 2009-06-04
KR20100092035A (ko) 2010-08-19
AR069437A1 (es) 2010-01-20
JP5244917B2 (ja) 2013-07-24
US20110224173A1 (en) 2011-09-15
ZA201001992B (en) 2010-12-29
CO6280421A2 (es) 2011-05-20
CR11362A (es) 2010-06-14
MA31895B1 (fr) 2010-12-01
TN2010000138A1 (en) 2011-09-26
US20090143337A1 (en) 2009-06-04
MX2010005786A (es) 2010-06-09
EP2225252A1 (en) 2010-09-08
CN101835787A (zh) 2010-09-15
AU2008328797A1 (en) 2009-06-04
TW200932248A (en) 2009-08-01
IL204657A0 (en) 2010-11-30
ECSP10010321A (es) 2010-08-31
JP2011504908A (ja) 2011-02-17
CA2701516A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
BRPI0922904A2 (pt) "compostos"
FR17C1014I2 (fr) Compositions fongicides
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI1015540A2 (pt) ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
EP2280916A4 (en) HYDROCHLORFLUOROLEFINZUSAMMENSETZUNGEN
BRPI0914746A2 (pt) composições fungicidas
ATE502948T1 (de) Substituierte bicyclolactamverbindungen
EP2183614A4 (en) DISTANCE ESTIMATING
ATE554776T1 (de) Antivirale phosphinatverbindungen
BRPI0914533A2 (pt) "métodos"
BRPI0914759A2 (pt) derivado de alquil pirimidin-4-ona substituída
BRPI0811433A2 (pt) compostos do tipo triazolil aminopirimidina
BRPI0720097A2 (pt) Compostos de fosfonato
EP2208972A4 (en) COMBINATION SCALE
EP2258697A4 (en) HYDROXYCHINOXALINCARBOXAMIDDERIVAT
EP2537831A4 (en) imidazole
MA30860B1 (fr) Myrtillier denomme "c97-390"
BRPI0811860A2 (pt) Compostos de (fenil)imidazolil)metilheteroarila
FR2936764B1 (fr) Couloir d'intercirculation
ES1068308Y (es) Zapatilla de baño
BRPI0820430A2 (pt) Composto
EP2328892A4 (en) Oxo-tetrahydrofuran-2-YL-benzimidazole derivative
DK2160386T3 (da) Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser
ES1065266Y (es) Deposito de compensacion
UA16823S (uk) Плащ «настя»

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.